Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T-DM1 in HER2-positive metastatic breast cancer patients with brain metastasis
2016-004398-41Phase 2Terminated
- Sponsor
- Institut Jules Bordet
- Start
- Dec 2017
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab emtansine in HER2-enriched breast cancer (HER2+), brain metastases, sponsored by Institut Jules Bordet. Started Dec 2017; status: terminated.
02
Drugs
trastuzumab emtansine
03
Conditions
HER2-enriched breast cancer (HER2+)brain metastases
Beyond the preview
Go deeper on 2016-004398-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004398-41.